Corrie's Shared Resources

GLP-1 Agonists’ Potential for Fibrosis Regression
In a recent review, researchers examined the molecular and clinical effects of glucagon-like peptide 1 (GLP-1) receptor agonists in treating...

Detecting Significant Fibrosis in Hispanic Patients With MASLD
A recent study evaluated the performance of noninvasive tests (NITs) for detecting significant fibrosis in Hispanic patients with metabolic dysfunction–associated...

Resmetirom and Advanced Liver Fibrosis
Resmetirom (MGL-3196) received accelerated FDA approval in March 2024 for treating MASH with moderate to advanced liver fibrosis (F2-F3). This...

Resmetirom FDA-Approved for MASH
In 2024, resmetirom (MGL-3196) became the first FDA-approved drug for MASH, demonstrating significant efficacy in resolving MASH without worsening fibrosis...

MASLD: The Growing Need for Early Intervention
MASLD (metabolic-associated steatotic liver disease) is the most common chronic liver disease in the US, affecting an estimated 31% of...

MASEF Score Promising for Early Detection of At-Risk MASH, Non-Invasive Alternative to VCTE
Early identification of patients with a NAFLD activity score ≥4 and significant fibrosis (≥F2) is crucial, as these individuals are...